دورية أكاديمية

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.

التفاصيل البيبلوغرافية
العنوان: Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
المؤلفون: Demel, U.M., Boger, M., Yousefian, S., Grunert, C., Zhang, L., Hotz, P.W., Gottschlich, A., Köse, H., Isaakidis, K., Vonficht, D., Grünschläger, F., Rohleder, E., Wagner, K., Dönig, J., Igl, V., Brzezicha, B., Baumgartner, F., Habringer, S., Löber, J., Chapuy, B., Weidinger, C., Kobold, S., Busse, A.B., Müller, S., Wirth, M., Schick, M., Keller, U.
المصدر: J. Clin. Invest. 132:e152383 (2022)
سنة النشر: 2022
المجموعة: PuSH - Publikationsserver des Helmholtz Zentrums München
مصطلحات موضوعية: Antigen Presentation, Immunology, Immunotherapy, Oncology, Ubiquitin-proteosome System
الوصف: Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells to evade CD8+ T cell-mediated immunosurveillance by suppressing the MHC class I (MHC-I) antigen-processing and presentation machinery (APM). Loss of the MHC-I APM is a frequent cause of resistance to cancer immunotherapies, and the pharmacological inhibition of SUMOylation (SUMOi) resulted in reduced activity of the transcriptional repressor scaffold attachment factor B (SAFB) and induction of the MHC-I APM. Consequently, SUMOi enhanced the presentation of antigens and the susceptibility of tumor cells to CD8+ T cell-mediated killing. Importantly, SUMOi also triggered the activation of CD8+ T cells and thereby drove a feed-forward loop amplifying the specific antitumor immune response. In summary, we showed that activated SUMOylation allowed tumor cells to evade antitumor immunosurveillance, and we have expanded the understanding of SUMOi as a rational therapeutic strategy for enhancing the efficacy of cancer immunotherapies.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 0021-9738
1558-8238
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35499080; info:eu-repo/semantics/altIdentifier/wos/WOS:000798531300001; info:eu-repo/semantics/altIdentifier/isbn/0021-9738; info:eu-repo/semantics/altIdent; https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=65031Test; urn:isbn:0021-9738; urn:issn:0021-9738; urn:issn:1558-8238
DOI: 10.1172/JCI152383
الإتاحة: https://doi.org/10.1172/JCI152383Test
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=65031Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.1F1950F4
قاعدة البيانات: BASE
الوصف
تدمد:00219738
15588238
DOI:10.1172/JCI152383